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In the last decades, due to aging communities and worse risk factor
proﬁles, incidences of peripheral artery disease (PAD) increased both in
western and developing countries and are predicted to drastically in-
crease globally in the next years [1,2]. Yet, PAD remains still highly
undetected [3]. Moreover, deﬁnitions and diagnostic assessment of PAD
widely diﬀer in the current literature. Clinicians will agree that com-
parability between intermittent claudication (IC) and a low ankle-bra-
chial index (ABI< 0.9), which might be asymptomatic, is not met. In
addition, the diagnosis of critical limb ischemia (CLI) in diabetic pa-
tients with feet ulcers without vascular assessment is weak. In this
mineﬁeld of problems, most of our evidence is derived from observa-
tional trials. Only a few randomized controlled trials like COMPASS-MI
[4] and FOURIER [5] with distinct PAD subgroups contributed stronger
evidence to our secondary prevention and therapy goals in PAD.
Nevertheless, guidelines challenged us to improve treatment of PAD
patients with stricter risk factor optimisation goals during the last
decade [6,7]. However, the big picture for the eﬀect of changes in
treatment of PAD was not drawn.
In this issue of Atherosclerosis, Agnelli et al. [8], accepted the chal-
lenge. The authors report results in terms of morbidity and mortality in
PAD patients of a meta-analysis with approximately 570,000 patients
with about 855,000 person-years out of 124 eligible studies from 2003
to 2017. They built the bridge between the vast amount of hetero-
geneity between RCTs (only 15%, n = 19) and observational studies.
Unfortunately, but expected, PAD and outcome deﬁnitions highly dif-
fered between the groups (ABI< 0.9 vs IC; diﬀering CLI criteria).
Nevertheless, the authors made remarkable ﬁndings with event rates
comparable to other atherosclerotic diseases with especially high event-
rates in the CLI branch. All-cause and cv mortality rates in patients with
an ABI< 0.9 were 113 and 39 per 1000 person-years, respectively, and
for CLI 183 and 81 per 1000 person-years, respectively. In fact, the
overall event-rate of 113 per 1000 person-years surpasses comparable
coronary heart disease data [9,10]. Interestingly, trials starting from
2008, after the publication of the TASC II guidelines [11] and the 2005
ACC/AHA PAD guidelines [12], had lower cv event-rates (36 vs 46 per
1000 person-years) than trials before 2008. Unfortunately, the authors
did not provide data on changes of secondary prevention medication
with the 2008 threshold, while generally there was need of improve-
ment, especially with only 55% of statin intake in the CLI subgroup (see
Table 1). Apart from the vast number of patients, the observation
period of approximately 1.3 years per patient remains short for out-
come analyses. In a subgroup analysis, the all-cause mortality event-
rate for studies with a long observation period (> 1.3 years) was lower
than in those with a short observation period (< 1.3 years) (Appendix
4b). Since 85% of these studies were of observational character, lost to
follow-up might have provoked this disparity. Furthermore, a wide
range of 25–468 events per 1000 person-years was found in the CLI
group and CLI patients had less outcome events in the RCT than in the
observational trial branch. Apart from the expectable better-than-real-
life situation in RCTs, these disparities indicate a proportion of mis-
diagnosed diabetic foot patients, which have worse outcome than CLI
patients, in the CLI branch. Interestingly, stroke rates were not higher in
CLI compared to PAD patients. However, one should be cautious with
this result, since only a small proportion of less than 15% of the ana-
lysed studies reported stroke events and the authors did not provide the
actual sample size of this sub-analysis.
So, what can we learn from the biggest up to date picture for PAD?
In fact, apart from the problems derived from the vast heterogeneity
of the studies analysed and the short observation period of approxi-
mately 1.3 years, the presented data teaches us the future direction for
the clinical pathway. All obstacles from diﬀering diagnostic assessment
and deﬁnitions to unmet treatment goals of PAD/CLI result in higher
mortality event-rates than in comparable atherosclerotic diseases of
diﬀerent vascular beds.
Thus, we as a community should tackle this problem and once again
raise awareness of PAD in the clinical setting. Furthermore, the de-
monstrated rates of secondary prevention therapy have a scope of im-
provement, especially in CLI patients. Thus, with the implementation of
recently proposed stricter treatment goals [7,13] future trials might
report smaller event-rates both in RCTs as well as observational trials.
In summary, the results of Agnelli et al. can be seen as a challenge
for optimisation both of diagnostic criteria and therapy of PAD in future
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